27,5371 Table 1 summarises key safety observations associated with GLP-1 receptor agonists across gastrointestinal, renal, hepatobiliary, pancreatic, thyroid, musculoskeletal, psychiatric, ocular, and dermatologic domains, as reported in previously published studies
TM: Writing original draft, Investigation, Data curation, Validation, Methodology
Why Choose Our Weight Loss Clinic in Hammond, IN
Retatrutide is part of a new class of medications known as multi-agonist peptides, designed to target multiple pathways involved in appetite regulation and metabolism
further suggest that semaglutide may impact the gut microbial community during treatment, and the basal microbiome may predict changes in HbA1c in semaglutide users (despite methodological limitations and the need for replication) ( Consistent with these findings, a recent clinical pilot study further demonstrated that liraglutide not only promoted weight reduction and improved glycemic control in patients with obesity and T2D, but also induced significant shifts in gut microbial composition ( and diversity) and metabolic pathways, reinforcing the concept that microbiota modulation may contribute to the therapeutic effects of GLP-1 RAs ( To synthesize the currently available human evidence, Table 1 summarizes clinical studies evaluating gut microbiota composition in patients receiving GLP-1 receptor agonists